Silence Therapeutics
SLN
71 hedge funds and large institutions have $502M invested in Silence Therapeutics in 2024 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 22 increasing their positions, 19 reducing their positions, and 5 closing their positions.
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
16% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 19
11% more funds holding
Funds holding: 64 → 71 (+7)
0.42% less ownership
Funds ownership: 19.87% → 19.45% (-0.42%)
15% less capital invested
Capital invested by funds: $588M → $502M (-$85.9M)
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FTM
First Turn Management
Del Mar,
California
|
+$11.4M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$10.8M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$9.36M |
| 4 |
Millennium Management
New York
|
+$7.94M |
| 5 |
SG Americas Securities
New York
|
+$7.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LOAME
Lombard Odier Asset Management (Europe)
London,
United Kingdom
|
-$48.3M |
| 2 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
-$11.4M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$6.04M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$3.14M |
| 5 |
OCA
Octagon Capital Advisors
New York
|
-$2.96M |
SLN Hedge Fund Activity: Q2 2024 in Review
71 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q2 2024, worth a combined $502M — down 15% from $588M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new SLN positions and 5 closed out — a net gain of 7 holders — while 22 added to existing stakes and 19 trimmed.
The largest buyer was First Turn Management, opening a new position worth an estimated $11.4M. The largest seller was Lombard Odier Asset Management (Europe), exiting entirely with an estimated $48.3M sold.
- 71 institutional investors held Silence Therapeutics (SLN) as of Q2 2024, up from 64 in Q1 2024.
- Funds reported $502M of Silence Therapeutics stock for Q2 2024, down 15% quarter-over-quarter.
- 12 funds opened new Silence Therapeutics positions in Q2 2024 and 5 closed out, a net change of +7 holders.
- The largest Silence Therapeutics buyer in Q2 2024 was First Turn Management, an estimated $11.4M added.
- The largest Silence Therapeutics seller in Q2 2024 was Lombard Odier Asset Management (Europe), an estimated $48.3M sold.
Based on aggregated 13F filings for Q2 2024.